Success Metrics

Clinical Success Rate
70.6%

Based on 12 completed trials

Completion Rate
71%(12/17)
Active Trials
0(0%)
Results Posted
83%(10 trials)
Terminated
5(26%)

Phase Distribution

Ph phase_2
13
68%
Ph not_applicable
4
21%
Ph phase_1
1
5%
Ph phase_3
1
5%

Phase Distribution

1

Early Stage

13

Mid Stage

1

Late Stage

Phase Distribution19 total trials
Phase 1Safety & dosage
1(5.3%)
Phase 2Efficacy & side effects
13(68.4%)
Phase 3Large-scale testing
1(5.3%)
N/ANon-phased studies
4(21.1%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

63.2%

12 of 19 finished

Non-Completion Rate

36.8%

7 ended early

Currently Active

0

trials recruiting

Total Trials

19

all time

Status Distribution
Completed(12)
Terminated(7)

Detailed Status

Completed12
Terminated5
Withdrawn2

Development Timeline

Analytics

Development Status

Total Trials
19
Active
0
Success Rate
70.6%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (5.3%)
Phase 213 (68.4%)
Phase 31 (5.3%)
N/A4 (21.1%)

Trials by Status

withdrawn211%
completed1263%
terminated526%

Recent Activity

Clinical Trials (19)

Showing 19 of 19 trials
NCT01761877Phase 2

NSAID Effects on Clinical and Imaging Breast Biomarkers

Completed
NCT00299195Not Applicable

A Randomized Study of Sulindac in Oral Premalignant Lesions

Completed
NCT00068419Phase 2

Sulindac and Tamoxifen in Treating Patients With Desmoid Tumor

Completed
NCT00841204Phase 2

Sulindac in Preventing Melanoma in Healthy Participants Who Are at Increased Risk of Melanoma

Completed
NCT00392665Phase 2

Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck

Terminated
NCT01843179Phase 2

Sulindac for Patients With AML

Withdrawn
NCT00335504Phase 2

Atorvastatin Calcium, Oligofructose-Enriched Inulin, or Sulindac in Preventing Cancer in Patients at Increased Risk of Developing Colorectal Neoplasia

Completed
NCT01187901Phase 2

A Clinical Trial of COX and EGFR Inhibition in Familial Polyposis Patients

Completed
NCT01856322Phase 2

Surgery Plus Sulindac or Surgery Alone for Advanced Colorectal Cancer

Terminated
NCT00343629Not Applicable

Sulindac Capsules Compared With Sulindac Tablets in Healthy Volunteers

Completed
NCT00118365Phase 3

Eflornithine and Sulindac in Preventing Colorectal Cancer in Patients With Colon Polyps

Completed
NCT00755976Phase 2

Sulindac and Epirubicin in Treating Patients With Metastatic Malignant Melanoma

Completed
NCT01636128Phase 2

Urinary Biomarker Study With Sulindac and Difluoromethylornithine

Withdrawn
NCT00368927Phase 2

Sulindac in Preventing Lung Cancer in Current or Former Smokers With Bronchial Dysplasia

Completed
NCT00039520Phase 2

Sulindac and Docetaxel in Treating Women With Metastatic or Recurrent Breast Cancer

Completed
NCT00245024Phase 1

Sulindac in Preventing Breast Cancer in Women at High Risk for Breast Cancer

Completed
NCT00062023Phase 2

Comparison of Sulindac, Aspirin, and Ursodiol in Preventing Colorectal Cancer

Terminated
NCT00003365Not Applicable

Sulindac and Plant Compounds in Preventing Colon Cancer

Terminated
NCT00176618Not Applicable

The Effects of Curcuminoids on Aberrant Crypt Foci in the Human Colon

Terminated

All 19 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
19